Kristof Van Dessel

Kristof Van Dessel

Auto-generated profile, based on publicly available information

Kristof Van Dessel

Faculty of Medicine and Health Sciences, Endocrinology-Diabetology, Antwerp University Hospital and University of Antwerp , 2650 Edegem

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2020 in Acta Clinica Belgica
Verified
Journal Article
Closed access
PLPatrick Lauwers
Patrick Lauwers
EDEveline Dirinck
Eveline Dirinck
SBSaskia Van Bouwel
Saskia Van Bouwel
AVAn Verrijken
An Verrijken
KDKristof Van Dessel
Kristof Van Dessel
JHJeroen Hendriks
Jeroen Hendriks
Malnutrition has a detrimental effect on wound healing; hence, it might influence the outcome in people with a diabetic foot ulcer (DFU).The aim of this manuscript is to overview studies that describe the prevalence of malnutrition in DFU patients and assess the relation between malnutrition, DFU severity, and outcome. A literature review was performed. Malnutrition had to be defined by anthropometry and/or validated screening and assessment tools. Five papers were included: one RCT, three prospective cohort studies and one retrospective observational study. A substantial number of patients were at risk for malnutrition (49%-70%) or were malnourished (15%-62%). In one study, nutritional status was related to DFU severity. Three authors demonstrated a negative influence of malnutrition on outcome. Two studies examined the prevalence of malnutrition after six months, but did not detect a decline in malnutrition rates. Despite a large heterogeneity, all papers indicated that malnutrition is highly prevalent among DFU patients. Notwithstanding the lack of unequivocal evidence, malnutrition might have a negative influence on DFU outcome. Therefore, clinicians should pay attention to the nutritional status of people with a DFU.Abbreviations: BMI: Body Mass Index; DFU: Diabetic Foot Ulcer; DM: Diabetes Mellitus; GNRI: Geriatric Nutritional Risk Index; HbA1c: Glycated Hemoglobin; IWGDF: International Working Group on the Diabetic Foot; LEA: Lower Extremity Amputation; MNA: Mini Nutritional Assessment; MNA-SF: Mini Nutritional Assessment-Short Form; MUST: Malnutrition Universal Screening Tool; NRS-2002: Nutritional Risk Screening-2002; PAD: Peripheral Arterial Disease; RCT: randomized controlled trial; SGA: Subjective Global Assessment.

2 January 2024 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
KDKristof Van Dessel
Kristof Van Dessel
AVAn Verrijken
An Verrijken
Christophe De BlockChristophe De Block
Christophe De Block
AVAnn Verhaegen
Ann Verhaegen
FPFrida Peiffer
Frida Peiffer
EDEveline Dirinck
Eveline Dirinck

1 June 2021 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
Patrick R.M. LauwersPatrick R.M. Lauwers
Patrick R.M. Lauwers
JHJeroen M.H. Hendriks
Jeroen M.H. Hendriks
SBSaskia Van Bouwel
Saskia Van Bouwel
AVAn Verrijken
An Verrijken
KDKristof Van Dessel
Kristof Van Dessel
EDEveline Dirinck
Eveline Dirinck

24 May 2019 in Nutrition & Diabetes
Verified
Journal Article
Open access
PDF file
LHLien Haverals
Lien Haverals
KDKristof Van Dessel
Kristof Van Dessel
AVAn Verrijken
An Verrijken
EDEveline Dirinck
Eveline Dirinck
FPFrida Peiffer
Frida Peiffer
LGLuc Van Gaal
Luc Van Gaal
Background/objectives: To study the importance and clinical usefulness of the 1-h plasma glucose (1hPG) in a Caucasian obese population with regard to the presence of prediabetes, diabetes, and metabolic syndrome (MetS). Subjects/methods: We conducted a cross-sectional study of 2439 overweight or obese subjects. All received an oral glucose tolerance test (OGTT) using the American Diabetes Association criteria. ROC-curves were used to compare the sensitivity and (1-specificity) of 1hPG versus FPG and 2hPG to diagnose prediabetes and diabetes. Results: Of 2439 patients (72.1% female) (age 43 ± 13 years, BMI 37.9 (34.6–41.6) kg/m2), 1262 (51.7%) had a 1hPG ≥ 155 mg/dL. The prevalence of prediabetes was 33.8% and of diabetes 9.8%. In these 240 diabetic patients, only 1.6% (four patients) did not show a 1hPG ≥ 155 mg/dL. Subjects with 1hPG ≥ 155 mg/dL were more insulin resistant (p < 0.001), had a higher waist (p < 0.001), visceral adipose tissue (VAT) (p < 0.001), systolic blood pressure (p < 0.001), microalbuminuria (p < 0.001), PAI-1 (p < 0.001), and worse lipid profile (p < 0.001) than subjects with 1hPG < 155 mg/dL. MetS was present in 64.1% of subjects with 1hPG ≥ 155 mg/dL versus 42.5% of subjects with 1hPG < 155 mg/dL (p < 0.001). In the group with 1hPG ≥ 155 mg/dL 32.6% had a normal glucose tolerance (NGT), 48.9% had prediabetes, and 18.5% was diagnosed with T2DM compared to 81.7% NGT, 17.7% prediabetes, and 0.6% T2DM in subjects with 1hPG < 155 mg/dL (p < 0.001). Among NGT subjects, 30.0% had a 1hPG ≥ 155 mg/dL and showed higher HOMA-IR (p = 0.008), VAT (p < 0.001), blood pressure (p < 0.001), and worse lipid profile (p = 0.001). Compared to 1hPG < 155 mg/dL, the sensitivity and specificity of 1hPG ≥ 155 mg/dL of prediabetes were 74.8% and 60.0% and for diabetes 97.1% and 53.2%, respectively. Conclusions: This study supports the role of 1hPG value as a valuable tool in the detection of obese subjects at high risk for T2DM and MetS.

27 January 2026 in Nutrition
Verified
Journal Article
Closed access
KDKristof Van Dessel
Kristof Van Dessel
Patrick R.M. LauwersPatrick R.M. Lauwers
Patrick R.M. Lauwers
AVAn Verrijken
An Verrijken
CBChristophe De Block
Christophe De Block
EDEveline Dirinck
Eveline Dirinck

16 September 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
ASAmber Sabbe
Amber Sabbe
NBNiels Bochanen
Niels Bochanen
ABAnnelies Van Den Broucke
Annelies Van Den Broucke
KMKatarina Mihaljčić
Katarina Mihaljčić
ABAxelle Bigaré
Axelle Bigaré
Christophe De BlockChristophe De Block
Christophe De Block
Context: Beyond HbA1c, continuous glucose monitoring (CGM) is now widely used in clinical practice, providing more detailed information about glycemic control. However, its ability to predict long-term microvascular outcomes in type 1 diabetes remains unclear. Objective: To evaluate the association between CGM-derived glucometrics and the 5-year incidence of microvascular complications, providing longitudinal real-world evidence in adults with type 1 diabetes. Design: Longitudinal real-world cohort study with 5-year follow-up. Setting: Tertiary referral center. Participants: Two hundred forty-six adults with type 1 diabetes (median age 40 [28-53] years, diabetes duration 24 [13-33] years). Intervention: No interventional treatment. Main Outcome Measure: Composite microvascular endpoint including nephropathy (persistent albuminuria ≥20 µg/min, estimated glomerular filtration rate <60 mL/min/1.73 m2, and/or renin–angiotensin–aldosterone system inhibitor use for albuminuria), severe retinopathy (proliferative retinopathy, maculopathy, and/or blindness), and peripheral neuropathy (monofilament score <6/6 and/or abnormal nerve conduction). Results: HbA1c decreased from 7.6% (59 mmol/mol) to 7.2% (55 mmol/mol), and time in range (TIR, 70-180 mg/dL) increased from 50 ± 14% to 61 ± 15%. All CGM-derived metrics (TIR, mean glucose, glucose management indicator) were associated with the composite endpoint. In this longitudinal real-world cohort, a ≥10% decrease in TIR was associated with higher complication rates (33.3%) compared with a stable TIR (7.9%) or ≥10% increase (15.0%) (P = .011). In multivariable analyses adjusted for age and baseline TIR, change in TIR (ΔTIR) remained independently associated with outcomes. Body mass index and systolic blood pressure were not significant. Models incorporating glucometrics and age showed acceptable discriminative performance (area under the curves 0.757-0.787). Conclusion: Continuous glucose monitoring–derived glucometrics were associated with the 5-year incidence of microvascular complications in this real-world cohort, with ΔTIR potentially providing additional prognostic information beyond glycated hemoglobin (HbA1c). Further validation is needed before routine clinical implementation.